Montgomery, Texas (September 21, 2016) – AngioSoma, Inc. (the ‘Company‘, ‘we‘, and ‘our‘), announces the formation of the Soma Nutraceuticals, Inc. subsidiary for the acquisition and marketing of proven nutraceutical products, as well as acquisition discussions with multiple proven nutraceutical intellectual properties. Our Chairman Emeritus “Doc” Summers owns some of the proven nutraceutical products we are reviewing for acquisition. The Company is recruiting subsidiary management which have a mass marketing nutraceutical product focus.
“If we could introduce my Stemulite™ products to the market again, I believe that we could achieve the revenue throughput that Endothil achieved at $10,000,000+ per year in 2008,” said Chairman Emeritus David “Doc” Summers.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://angiosoma.com) is a clinical stage bio-pharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (‘PAD‘). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration (‘FDA’) approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.